CINV Existing and Pipeline Drugs Market Size, Share, Growth 2032

CINV Existing and Pipeline Drugs Market Size by Drug Type, End Use, Region, Industry-Wide Analysis, Competitive Landscape Assessment & Long-Term Forecast to 2032

4.9%

CAGR (2025-2032)

1.69 USD Bn.

Market Size

329

Report Pages

125

Market Tables

Overview

The CINV Existing and Pipeline Drugs Market size was valued at USD 1.69 Billion in 2024 and the total CINV Existing and Pipeline Drugs revenue is expected to grow at a CAGR of 4.9% from 2025 to 2032, reaching nearly USD 2.49 Billion.

CINV Existing and Pipeline Drugs Market Drivers and Restrains

Nausea and vomiting are the two most common side effects associated with cancer chemotherapy, and are referred to as chemotherapy induced nausea and vomiting (CINV). Rising prevalence of various types of cancer is fueling the growth of Global Market during forecast period.

Technological advances for invention of new drugs are driving global market. Chemotherapy has helped millions of people in their battle against cancer, also chemotherapy supports to destroy cancer cells. Unfortunately, healthy noncancerous cells are sometimes destroyed and this can lead to unpleasant side effects this may cause major restraint to global market. The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis.To know about the Research Methodology :- Request Free Sample Report

CINV Existing and Pipeline Drugs Market key segmentation

Global market is segmented into By Drug type and By End-use. Based on Drug Type the market is categorized in to Akynzeo (netupitant-palonosetron), Emend (aprepitant), Aloxi (palonosetron), Zofran Generic (ondansetron), Kytril Generic (granisetron), SUSTOL (extended release granisetron injection), Rolapitant. Among these Aloxi is expected lucrative share of global market as this drug is known as a second-generation serotonin receptor blocker.

In most situations, these drugs are very safe to take and have minimal side effects. Based on By End-use the global market is divided in to Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics, Hospital Pharmacies, and Drugstores. Among these hospitals segment emerged as the fastest growing segment during forecast period. Rising patient population is responsible for this segmental growth.

CINV Existing and Pipeline Drugs Market Regional Analysis

Based on region global market is segmented in to Asia Pacific, North America, Europe, Latin America, and Middle East Africa. Among these North America holds the largest share of global market. Because of approval of rolapitant and Sustol drugs the market is growing with significant CAGR of xx% during forecast period. Europe emerged as the second largest market for CINV drugs after North America.

The launch of CINV pipeline drugs in Europe is expected to be a year later than in North America, given the delays on the past launches of CINV drugs such as Aloxi and Emend. Asia-Pacific is expected to grow with moderate CAGR of xx% during forecast period , the rising incidences of various types of cancer is responsible for increased growth rate in this region.

The objective of the report is to present comprehensive analysis of global market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region.

PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers.

The report also helps in understanding global market dynamics, structure by analyzing the market segments, and project the Global market size. Clear representation of competitive analysis of key players by Thyroid Gland Disorders Treatment Type, price, financial position, product portfolio, growth strategies, and regional presence in the global market make the report investor’s guide.

Scope of Global CINV Existing and Pipeline Drugs Market: Inquire before buying

Global CINV Existing and Pipeline Drugs Market
Report Coverage	Details
Base Year:	2024	Forecast Period:	2025-2032
Historical Data:	2019 to 2024	Market Size in 2024:	USD 1.69 Bn.
Forecast Period 2025 to 2032 CAGR:	4.9%	Market Size in 2032:	USD 2.49 Bn.
Segments Covered:	by Drug Type	Akynzeo (netupitant-palonosetron), Emend (aprepitant), Aloxi (palonosetron), Zofran Generic (ondansetron), Kytril Generic (granisetron), SUSTOL (extended release granisetron injection), Rolapitant
	by End Use	Hospitals Specialty Clinics Hospital Pharmacies Drugstores

CINV Existing and Pipeline Drugs by Region

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria, Turkey, Russia and Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina, Columbia and Rest of South America)

CINV Existing and Pipeline Drugs Key Players are:

1. GlaxoSmithKline
2. Helsinn
3. Heron Therapeutics
4. Merck
5. Tesaro
6. Eastman
7. Lonza
8. CHEMIDEA CHEMICALS
9. Teva pharmaceutical
10. Baxter Healthcare,
11. Sun Pharma,
12. Mylan Pharmaceuticals, Inc.,
13. Sandoz (Novartis AG),
14. Barr Laboratories, Inc.
15. Orchid Healthcare
16. Acacia Pharma
17. TALLC Corporation
18. LP Pharmaceuticals

Frequently Asked Questions:

1. Which region has the largest share in Global CINV Existing and Pipeline Drugs Market?
Ans: North America region held the highest share in 2024.

2. What is the growth rate of Global CINV Existing and Pipeline Drugs Market?
Ans: The Global CINV Existing and Pipeline Drugs Market is growing at a CAGR of 4.9% during forecasting period 2025-2032.

3. What is scope of the Global CINV Existing and Pipeline Drugs Market report?
Ans: Global CINV Existing and Pipeline Drugs Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Global CINV Existing and Pipeline Drugs Market?
Ans: The important key players in the Global CINV Existing and Pipeline Drugs Market are – GlaxoSmithKline, Helsinn, Heron Therapeutics, Merck, Tesaro, Eastman, Lonza, CHEMIDEA CHEMICALS, Teva pharmaceutical, Baxter Healthcare,, Sun Pharma,, Mylan Pharmaceuticals, Inc.,, Sandoz (Novartis AG),, Barr Laboratories, Inc., Orchid Healthcare, Acacia Pharma, TALLC Corporation, LP Pharmaceuticals.

5. What was the Global CINV Existing and Pipeline Drugs Market size in 2024?
Ans: The Global CINV Existing and Pipeline Drugs Market size was USD 1.69 Billion in 2024.

Global CINV Existing and Pipeline Drugs Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global CINV Existing and Pipeline Drugs Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 4.8. Patent Registration 5. Supply Side and Demand Side Indicators 6. Global CINV Existing and Pipeline Drugs Market Analysis and Forecast 6.1. Global CINV Existing and Pipeline Drugs Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global CINV Existing and Pipeline Drugs Market Analysis and Forecast, By Drug type 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global CINV Existing and Pipeline Drugs Market Value Share Analysis, By Drug type 7.4. Global CINV Existing and Pipeline Drugs Market Size (US$ Bn) Forecast, By Drug type 7.5. Global CINV Existing and Pipeline Drugs Market Analysis, By Drug type 7.6. Global CINV Existing and Pipeline Drugs Market Attractiveness Analysis, By Drug type 8. Global CINV Existing and Pipeline Drugs Market Analysis and Forecast, By End-Use 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global CINV Existing and Pipeline Drugs Market Value Share Analysis, By End-Use 8.4. Global CINV Existing and Pipeline Drugs Market Size (US$ Bn) Forecast, By End-Use 8.5. Global CINV Existing and Pipeline Drugs Market Analysis, By End-Use 8.6. Global CINV Existing and Pipeline Drugs Market Attractiveness Analysis, By End-Use 9. Global CINV Existing and Pipeline Drugs Market Analysis, by Region 9.1. Global CINV Existing and Pipeline Drugs Market Value Share Analysis, by Region 9.2. Global CINV Existing and Pipeline Drugs Market Size (US$ Bn) Forecast, by Region 9.3. Global CINV Existing and Pipeline Drugs Market Attractiveness Analysis, by Region 10. North America CINV Existing and Pipeline Drugs Market Analysis 10.1. Key Findings 10.2. North America CINV Existing and Pipeline Drugs Market Overview 10.3. North America CINV Existing and Pipeline Drugs Market Value Share Analysis, By Drug type 10.4. North America CINV Existing and Pipeline Drugs Market Forecast, By Drug type 10.4.1. Akynzeo (netupitant-palonosetron), 10.4.2. Emend (aprepitant), 10.4.3. Aloxi (palonosetron), 10.4.4. Zofran Generic (ondansetron), 10.4.5. Kytril Generic (granisetron), 10.4.6. SUSTOL (extended release granisetron injection), 10.4.7. Rolapitant 10.5. North America CINV Existing and Pipeline Drugs Market Value Share Analysis, By End-Use 10.6. North America CINV Existing and Pipeline Drugs Market Forecast, By End-Use 10.6.1. Hospitals 10.6.2. Specialty Clinics 10.6.3. Diagnostic Centers Therapeutics 10.6.4. Hospital Pharmacies 10.6.5. Drugstores 10.7. North America CINV Existing and Pipeline Drugs Market Value Share Analysis, by Country 10.8. North America CINV Existing and Pipeline Drugs Market Forecast, by Country 10.8.1. U.S. 10.8.2. Canada 10.9. North America CINV Existing and Pipeline Drugs Market Analysis, by Country 10.10. U.S. CINV Existing and Pipeline Drugs Market Forecast, By Drug type 10.10.1. Akynzeo (netupitant-palonosetron), 10.10.2. Emend (aprepitant), 10.10.3. Aloxi (palonosetron), 10.10.4. Zofran Generic (ondansetron), 10.10.5. Kytril Generic (granisetron), 10.10.6. SUSTOL (extended release granisetron injection), 10.10.7. Rolapitant 10.11. U.S. CINV Existing and Pipeline Drugs Market Forecast, By End-Use 10.11.1. Hospitals 10.11.2. Specialty Clinics 10.11.3. Diagnostic Centers Therapeutics 10.11.4. Hospital Pharmacies 10.11.5. Drugstores 10.12. Canada CINV Existing and Pipeline Drugs Market Forecast, By Drug type 10.12.1. Akynzeo (netupitant-palonosetron), 10.12.2. Emend (aprepitant), 10.12.3. Aloxi (palonosetron), 10.12.4. Zofran Generic (ondansetron), 10.12.5. Kytril Generic (granisetron), 10.12.6. SUSTOL (extended release granisetron injection), 10.12.7. Rolapitant 10.13. Canada CINV Existing and Pipeline Drugs Market Forecast, By End-Use 10.13.1. Hospitals 10.13.2. Specialty Clinics 10.13.3. Diagnostic Centers Therapeutics 10.13.4. Hospital Pharmacies 10.13.5. Drugstores 10.14. North America CINV Existing and Pipeline Drugs Market Attractiveness Analysis 10.14.1. By Drug type 10.14.2. By End-Use 10.15. PEST Analysis 10.16. Key Trends 10.17. Key Development 11. Europe CINV Existing and Pipeline Drugs Market Analysis 11.1. Key Findings 11.2. Europe CINV Existing and Pipeline Drugs Market Overview 11.3. Europe CINV Existing and Pipeline Drugs Market Value Share Analysis, By Drug type 11.4. Europe CINV Existing and Pipeline Drugs Market Forecast, By Drug type 11.4.1. Akynzeo (netupitant-palonosetron), 11.4.2. Emend (aprepitant), 11.4.3. Aloxi (palonosetron), 11.4.4. Zofran Generic (ondansetron), 11.4.5. Kytril Generic (granisetron), 11.4.6. SUSTOL (extended release granisetron injection), 11.4.7. Rolapitant 11.5. Europe CINV Existing and Pipeline Drugs Market Value Share Analysis, By End-Use 11.6. Europe CINV Existing and Pipeline Drugs Market Forecast, By End-Use 11.6.1. Hospitals 11.6.2. Specialty Clinics 11.6.3. Diagnostic Centers Therapeutics 11.6.4. Hospital Pharmacies 11.6.5. Drugstores 11.7. Europe CINV Existing and Pipeline Drugs Market Value Share Analysis, by Country 11.8. Europe CINV Existing and Pipeline Drugs Market Forecast, by Country 11.8.1. Germany 11.8.2. U.K. 11.8.3. France 11.8.4. Italy 11.8.5. Spain 11.8.6. Rest of Europe 11.9. Europe CINV Existing and Pipeline Drugs Market Analysis, by Country 11.10. Germany CINV Existing and Pipeline Drugs Market Forecast, By Drug type 11.10.1. Akynzeo (netupitant-palonosetron), 11.10.2. Emend (aprepitant), 11.10.3. Aloxi (palonosetron), 11.10.4. Zofran Generic (ondansetron), 11.10.5. Kytril Generic (granisetron), 11.10.6. SUSTOL (extended release granisetron injection), 11.10.7. Rolapitant 11.11. Germany CINV Existing and Pipeline Drugs Market Forecast, By End-Use 11.11.1. Hospitals 11.11.2. Specialty Clinics 11.11.3. Diagnostic Centers Therapeutics 11.11.4. Hospital Pharmacies 11.11.5. Drugstores 11.12. U.K. CINV Existing and Pipeline Drugs Market Forecast, By Drug type 11.12.1. Akynzeo (netupitant-palonosetron), 11.12.2. Emend (aprepitant), 11.12.3. Aloxi (palonosetron), 11.12.4. Zofran Generic (ondansetron), 11.12.5. Kytril Generic (granisetron), 11.12.6. SUSTOL (extended release granisetron injection), 11.12.7. Rolapitant 11.13. U.K. CINV Existing and Pipeline Drugs Market Forecast, By End-Use 11.13.1. Hospitals 11.13.2. Specialty Clinics 11.13.3. Diagnostic Centers Therapeutics 11.13.4. Hospital Pharmacies 11.13.5. Drugstores 11.14. France CINV Existing and Pipeline Drugs Market Forecast, By Drug type 11.14.1. Akynzeo (netupitant-palonosetron), 11.14.2. Emend (aprepitant), 11.14.3. Aloxi (palonosetron), 11.14.4. Zofran Generic (ondansetron), 11.14.5. Kytril Generic (granisetron), 11.14.6. SUSTOL (extended release granisetron injection), 11.14.7. Rolapitant 11.15. France CINV Existing and Pipeline Drugs Market Forecast, By End-Use 11.15.1. Hospitals 11.15.2. Specialty Clinics 11.15.3. Diagnostic Centers Therapeutics 11.15.4. Hospital Pharmacies 11.15.5. Drugstores 11.16. Italy CINV Existing and Pipeline Drugs Market Forecast, By Drug type 11.16.1. Akynzeo (netupitant-palonosetron), 11.16.2. Emend (aprepitant), 11.16.3. Aloxi (palonosetron), 11.16.4. Zofran Generic (ondansetron), 11.16.5. Kytril Generic (granisetron), 11.16.6. SUSTOL (extended release granisetron injection), 11.16.7. Rolapitant 11.17. Italy CINV Existing and Pipeline Drugs Market Forecast, By End-Use 11.17.1. Hospitals 11.17.2. Specialty Clinics 11.17.3. Diagnostic Centers Therapeutics 11.17.4. Hospital Pharmacies 11.17.5. Drugstores 11.18. Spain CINV Existing and Pipeline Drugs Market Forecast, By Drug type 11.18.1. Akynzeo (netupitant-palonosetron), 11.18.2. Emend (aprepitant), 11.18.3. Aloxi (palonosetron), 11.18.4. Zofran Generic (ondansetron), 11.18.5. Kytril Generic (granisetron), 11.18.6. SUSTOL (extended release granisetron injection), 11.18.7. Rolapitant 11.19. Spain CINV Existing and Pipeline Drugs Market Forecast, By End-Use 11.19.1. Hospitals 11.19.2. Specialty Clinics 11.19.3. Diagnostic Centers Therapeutics 11.19.4. Hospital Pharmacies 11.19.5. Drugstores 11.20. Rest of Europe CINV Existing and Pipeline Drugs Market Forecast, By Drug type 11.20.1. Akynzeo (netupitant-palonosetron), 11.20.2. Emend (aprepitant), 11.20.3. Aloxi (palonosetron), 11.20.4. Zofran Generic (ondansetron), 11.20.5. Kytril Generic (granisetron), 11.20.6. SUSTOL (extended release granisetron injection), 11.20.7. Rolapitant 11.21. Rest of Europe CINV Existing and Pipeline Drugs Market Forecast, By End-Use 11.21.1. Hospitals 11.21.2. Specialty Clinics 11.21.3. Diagnostic Centers Therapeutics 11.21.4. Hospital Pharmacies 11.21.5. Drugstores 11.22. Europe CINV Existing and Pipeline Drugs Market Attractiveness Analysis 11.22.1. By Drug type 11.22.2. By End-Use 11.23. PEST Analysis 11.24. Key Trend 11.25. Key Development 12. Asia Pacific CINV Existing and Pipeline Drugs Market Analysis 12.1. Key Findings 12.2. Asia Pacific CINV Existing and Pipeline Drugs Market Overview 12.3. Asia Pacific CINV Existing and Pipeline Drugs Market Value Share Analysis, By Drug type 12.4. Asia Pacific CINV Existing and Pipeline Drugs Market Forecast, By Drug type 12.4.1. Akynzeo (netupitant-palonosetron), 12.4.2. Emend (aprepitant), 12.4.3. Aloxi (palonosetron), 12.4.4. Zofran Generic (ondansetron), 12.4.5. Kytril Generic (granisetron), 12.4.6. SUSTOL (extended release granisetron injection), 12.4.7. Rolapitant 12.5. Asia Pacific CINV Existing and Pipeline Drugs Market Value Share Analysis, By End-Use 12.6. Asia Pacific CINV Existing and Pipeline Drugs Market Forecast, By End-Use 12.6.1. Hospitals 12.6.2. Specialty Clinics 12.6.3. Diagnostic Centers Therapeutics 12.6.4. Hospital Pharmacies 12.6.5. Drugstores 12.7. Asia Pacific CINV Existing and Pipeline Drugs Market Value Share Analysis, by Country 12.8. Asia Pacific CINV Existing and Pipeline Drugs Market Forecast, by Country 12.8.1. China 12.8.2. India 12.8.3. Japan 12.8.4. ASEAN 12.8.5. Rest of Asia Pacific 12.9. Asia Pacific CINV Existing and Pipeline Drugs Market Analysis, by Country 12.10. China CINV Existing and Pipeline Drugs Market Forecast, By Drug type 12.10.1. Akynzeo (netupitant-palonosetron), 12.10.2. Emend (aprepitant), 12.10.3. Aloxi (palonosetron), 12.10.4. Zofran Generic (ondansetron), 12.10.5. Kytril Generic (granisetron), 12.10.6. SUSTOL (extended release granisetron injection), 12.10.7. Rolapitant 12.11. China CINV Existing and Pipeline Drugs Market Forecast, By End-Use 12.11.1. Hospitals 12.11.2. Specialty Clinics 12.11.3. Diagnostic Centers Therapeutics 12.11.4. Hospital Pharmacies 12.11.5. Drugstores 12.12. India CINV Existing and Pipeline Drugs Market Forecast, By Drug type 12.12.1. Akynzeo (netupitant-palonosetron), 12.12.2. Emend (aprepitant), 12.12.3. Aloxi (palonosetron), 12.12.4. Zofran Generic (ondansetron), 12.12.5. Kytril Generic (granisetron), 12.12.6. SUSTOL (extended release granisetron injection), 12.12.7. Rolapitant 12.13. India CINV Existing and Pipeline Drugs Market Forecast, By End-Use 12.13.1. Hospitals 12.13.2. Specialty Clinics 12.13.3. Diagnostic Centers Therapeutics 12.13.4. Hospital Pharmacies 12.13.5. Drugstores 12.14. Japan CINV Existing and Pipeline Drugs Market Forecast, By Drug type 12.14.1. Akynzeo (netupitant-palonosetron), 12.14.2. Emend (aprepitant), 12.14.3. Aloxi (palonosetron), 12.14.4. Zofran Generic (ondansetron), 12.14.5. Kytril Generic (granisetron), 12.14.6. SUSTOL (extended release granisetron injection), 12.14.7. Rolapitant 12.15. Japan CINV Existing and Pipeline Drugs Market Forecast, By End-Use 12.15.1. Hospitals 12.15.2. Specialty Clinics 12.15.3. Diagnostic Centers Therapeutics 12.15.4. Hospital Pharmacies 12.15.5. Drugstores 12.16. ASEAN CINV Existing and Pipeline Drugs Market Forecast, By Drug type 12.16.1. Akynzeo (netupitant-palonosetron), 12.16.2. Emend (aprepitant), 12.16.3. Aloxi (palonosetron), 12.16.4. Zofran Generic (ondansetron), 12.16.5. Kytril Generic (granisetron), 12.16.6. SUSTOL (extended release granisetron injection), 12.16.7. Rolapitant 12.17. ASEAN CINV Existing and Pipeline Drugs Market Forecast, By End-Use 12.17.1. Hospitals 12.17.2. Specialty Clinics 12.17.3. Diagnostic Centers Therapeutics 12.17.4. Hospital Pharmacies 12.17.5. Drugstores 12.18. Rest of Asia Pacific CINV Existing and Pipeline Drugs Market Forecast, By Drug type 12.18.1. Akynzeo (netupitant-palonosetron), 12.18.2. Emend (aprepitant), 12.18.3. Aloxi (palonosetron), 12.18.4. Zofran Generic (ondansetron), 12.18.5. Kytril Generic (granisetron), 12.18.6. SUSTOL (extended release granisetron injection), 12.18.7. Rolapitant 12.19. Rest of Asia Pacific CINV Existing and Pipeline Drugs Market Forecast, By End-Use 12.19.1. Hospitals 12.19.2. Specialty Clinics 12.19.3. Diagnostic Centers Therapeutics 12.19.4. Hospital Pharmacies 12.19.5. Drugstores 12.20. Asia Pacific CINV Existing and Pipeline Drugs Market Attractiveness Analysis 12.20.1. By Drug type 12.20.2. By End-Use 12.21. PEST Analysis 12.22. Key Trend 12.23. Key Development 13. Middle East & Africa CINV Existing and Pipeline Drugs Market Analysis 13.1. Key Findings 13.2. Middle East & Africa CINV Existing and Pipeline Drugs Market Overview 13.3. Middle East & Africa CINV Existing and Pipeline Drugs Market Value Share Analysis, By Drug type 13.4. Middle East & Africa CINV Existing and Pipeline Drugs Market Forecast, By Drug type 13.4.1. Akynzeo (netupitant-palonosetron), 13.4.2. Emend (aprepitant), 13.4.3. Aloxi (palonosetron), 13.4.4. Zofran Generic (ondansetron), 13.4.5. Kytril Generic (granisetron), 13.4.6. SUSTOL (extended release granisetron injection), 13.4.7. Rolapitant 13.5. Middle East & Africa CINV Existing and Pipeline Drugs Market Value Share Analysis, By End-Use 13.6. Middle East & Africa CINV Existing and Pipeline Drugs Market Forecast, By End-Use 13.6.1. Hospitals 13.6.2. Specialty Clinics 13.6.3. Diagnostic Centers Therapeutics 13.6.4. Hospital Pharmacies 13.6.5. Drugstores 13.7. Middle East & Africa CINV Existing and Pipeline Drugs Market Value Share Analysis, by Country 13.8. Middle East & Africa CINV Existing and Pipeline Drugs Market Forecast, by Country 13.8.1. GCC 13.8.2. South Africa 13.8.3. Rest of Middle East & Africa 13.9. Middle East & Africa CINV Existing and Pipeline Drugs Market Analysis, by Country 13.10. GCC CINV Existing and Pipeline Drugs Market Forecast, By Drug type 13.10.1. Akynzeo (netupitant-palonosetron), 13.10.2. Emend (aprepitant), 13.10.3. Aloxi (palonosetron), 13.10.4. Zofran Generic (ondansetron), 13.10.5. Kytril Generic (granisetron), 13.10.6. SUSTOL (extended release granisetron injection), 13.10.7. Rolapitant 13.11. GCC CINV Existing and Pipeline Drugs Market Forecast, By End-Use 13.11.1. Hospitals 13.11.2. Specialty Clinics 13.11.3. Diagnostic Centers Therapeutics 13.11.4. Hospital Pharmacies 13.11.5. Drugstores 13.12. South Africa CINV Existing and Pipeline Drugs Market Forecast, By Drug type 13.12.1. Akynzeo (netupitant-palonosetron), 13.12.2. Emend (aprepitant), 13.12.3. Aloxi (palonosetron), 13.12.4. Zofran Generic (ondansetron), 13.12.5. Kytril Generic (granisetron), 13.12.6. SUSTOL (extended release granisetron injection), 13.12.7. Rolapitant 13.13. South Africa CINV Existing and Pipeline Drugs Market Forecast, By End-Use 13.13.1. Hospitals 13.13.2. Specialty Clinics 13.13.3. Diagnostic Centers Therapeutics 13.13.4. Hospital Pharmacies 13.13.5. Drugstores 13.14. Rest of Middle East & Africa CINV Existing and Pipeline Drugs Market Forecast, By Drug type 13.14.1. Akynzeo (netupitant-palonosetron), 13.14.2. Emend (aprepitant), 13.14.3. Aloxi (palonosetron), 13.14.4. Zofran Generic (ondansetron), 13.14.5. Kytril Generic (granisetron), 13.14.6. SUSTOL (extended release granisetron injection), 13.14.7. Rolapitant 13.15. Rest of Middle East & Africa CINV Existing and Pipeline Drugs Market Forecast, By End-Use 13.15.1. Hospitals 13.15.2. Specialty Clinics 13.15.3. Diagnostic Centers Therapeutics 13.15.4. Hospital Pharmacies 13.15.5. Drugstores 13.16. Middle East & Africa CINV Existing and Pipeline Drugs Market Attractiveness Analysis 13.16.1. By Drug type 13.16.2. By End-Use 13.17. PEST Analysis 13.18. Key Trend 13.19. Key Development 14. South America CINV Existing and Pipeline Drugs Market Analysis 14.1. Key Findings 14.2. South America CINV Existing and Pipeline Drugs Market Overview 14.3. South America CINV Existing and Pipeline Drugs Market Value Share Analysis, By Drug type 14.4. South America CINV Existing and Pipeline Drugs Market Forecast, By Drug type 14.4.1. Akynzeo (netupitant-palonosetron), 14.4.2. Emend (aprepitant), 14.4.3. Aloxi (palonosetron), 14.4.4. Zofran Generic (ondansetron), 14.4.5. Kytril Generic (granisetron), 14.4.6. SUSTOL (extended release granisetron injection), 14.4.7. Rolapitant 14.5. South America CINV Existing and Pipeline Drugs Market Value Share Analysis, By End-Use 14.6. South America CINV Existing and Pipeline Drugs Market Forecast, By End-Use 14.6.1. Hospitals 14.6.2. Specialty Clinics 14.6.3. Diagnostic Centers Therapeutics 14.6.4. Hospital Pharmacies 14.6.5. Drugstores 14.7. South America CINV Existing and Pipeline Drugs Market Value Share Analysis, by Country 14.8. South America CINV Existing and Pipeline Drugs Market Forecast, by Country 14.8.1. Brazil 14.8.2. Mexico 14.8.3. Rest of South America 14.9. Brazil CINV Existing and Pipeline Drugs Market Forecast, By Drug type 14.9.1. Akynzeo (netupitant-palonosetron), 14.9.2. Emend (aprepitant), 14.9.3. Aloxi (palonosetron), 14.9.4. Zofran Generic (ondansetron), 14.9.5. Kytril Generic (granisetron), 14.9.6. SUSTOL (extended release granisetron injection), 14.9.7. Rolapitant 14.10. Brazil CINV Existing and Pipeline Drugs Market Forecast, By End-Use 14.10.1. Hospitals 14.10.2. Specialty Clinics 14.10.3. Diagnostic Centers Therapeutics 14.10.4. Hospital Pharmacies 14.10.5. Drugstores 14.11. Mexico CINV Existing and Pipeline Drugs Market Forecast, By Drug type 14.11.1. Akynzeo (netupitant-palonosetron), 14.11.2. Emend (aprepitant), 14.11.3. Aloxi (palonosetron), 14.11.4. Zofran Generic (ondansetron), 14.11.5. Kytril Generic (granisetron), 14.11.6. SUSTOL (extended release granisetron injection), 14.11.7. Rolapitant 14.12. Mexico CINV Existing and Pipeline Drugs Market Forecast, By End-Use 14.12.1. Hospitals 14.12.2. Specialty Clinics 14.12.3. Diagnostic Centers Therapeutics 14.12.4. Hospital Pharmacies 14.12.5. Drugstores 14.13. Rest of South America CINV Existing and Pipeline Drugs Market Forecast, By Drug type 14.13.1. Akynzeo (netupitant-palonosetron), 14.13.2. Emend (aprepitant), 14.13.3. Aloxi (palonosetron), 14.13.4. Zofran Generic (ondansetron), 14.13.5. Kytril Generic (granisetron), 14.13.6. SUSTOL (extended release granisetron injection), 14.13.7. Rolapitant 14.14. Rest of South America CINV Existing and Pipeline Drugs Market Forecast, By End-Use 14.14.1. Hospitals 14.14.2. Specialty Clinics 14.14.3. Diagnostic Centers Therapeutics 14.14.4. Hospital Pharmacies 14.14.5. Drugstores 14.15. South America CINV Existing and Pipeline Drugs Market Attractiveness Analysis 14.15.1. By Drug type 14.15.2. By End-Use 14.16. PEST Analysis 14.17. Key Trend 14.18. Key Development 15. Company Profiles 15.1. Market Share Analysis, by Company 15.2. Competition Matrix 15.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 15.2.2. New Drug type Launches and Drug type Enhancements 15.2.3. Market Consolidation 15.2.3.1. M&A by Regions, Investment and Applications 15.2.3.2. M&A Key Players, Forward Integration and Backward Integration 15.3. Company Profiles: Key Players 15.3.1. GlaxoSmithKline 15.3.1.1. Company Overview 15.3.1.2. Financial Overview 15.3.1.3. Drug type Portfolio 15.3.1.4. Business Strategy 15.3.1.5. Recent Developments 15.3.1.6. Company Footprint 15.3.2. Helsinn 15.3.3. Heron Therapeutics 15.3.4. Merck 15.3.5. Tesaro 15.3.6. Eastman 15.3.7. Lonza 15.3.8. CHEMIDEA CHEMICALS 15.3.9. Teva pharmaceutical 15.3.10. Baxter Healthcare, 15.3.11. Sun Pharma, 15.3.12. Mylan Pharmaceuticals, Inc., 15.3.13. Sandoz (Novartis AG), 15.3.14. Barr Laboratories, Inc. 15.3.15. Orchid Healthcare 15.3.16. Acacia Pharma 15.3.17. TALLC Corporation 15.3.18. LP Pharmaceuticals 16. Primary Key Insights

Global CINV Existing and Pipeline Drugs Market